

Quinolone Antibacterials

Contributors

D. Beermann, T. Bergan, W. Christ, W.A. Craig,
S.E. Critchlow, A. Dalhoff, M.J. Everett, K. Grohe,
J. Kuhlmann, H. Lode, A. Maxwell, U. Petersen,
L.J.V. Piddock, E. Rubinstein, P. Schacht, H.-G. Schäfer,
T. Schenke, S. Segev, J.T. Smith (†), R. Stahlmann,
C. Thornsberry, E. von Keutz, H.-J. Zeiler

Editors

J. Kuhlmann, A. Dalhoff and H.-J. Zeiler



Springer

Contents

CHAPTER 1

History and Introduction

J.T. SMITH and H.-J. ZEILER. With 1 Figure	1
A. Chemistry	1
B. Antibacterial Activity	4
C. Oxygen and 4-Quinolones	6
D. 4-Quinolone Kinetics and Distribution in Humans	6
E. Outlook	8
References	9

CHAPTER 2

The Chemistry of the Quinolones: Methods of Synthesizing the Quinolone Ring System

K. GROHE. With 42 Figures	13
A. Introduction	13
B. Methods of Synthesizing the Quinolone Ring System.....	16
I. Gould-Jacobs Reaction	16
II. Dieckmann Cyclization of Diesters	21
III. Cycloaracylation Procedure	25
IV. Biere and Seelen Approach	35
V. Isatoic Anhydride Procedure	35
VI. Camps Quinolone Synthesis	39
VII. Meth-Cohn Quinolone Synthesis	41
VIII. Synthesis of Quinolone Analogues	42
IX. Synthesis of 4-Cinnolone-3-carboxylic Acids	45
X. Synthesis of 4-Pyridone-3-carboxylic Acids	49
References	52

CHAPTER 3

The Chemistry of the Quinolones: Chemistry in the Periphery of the Quinolones

U. PETERSEN and T. SCHENKE. With 35 Figures	63
---	----

A. Introduction	63
B. 1-Position	63
C. 2-Position	65
D. 3-Position	65
E. 4-Position	71
F. 5-Position	71
G. 6-Position	76
H. 7-Position	78
I. Synthesis of Specific Amines	78
1. Bicyclic Piperazine Derivatives	78
2. Aminopyrrolidine and Aminomethylpyrrolidine Derivatives	79
3. 3,4-Bridged Pyrrolidine Derivatives	83
4. Mixed Derivatives	88
II. C-N Linkage	89
III. C-S Linkage	94
IV. C-O Linkage	95
V. C-C Linkage	95
I. 8-Position	99
References	101

CHAPTER 4

Mode of Action

A. MAXWELL and S.E. CRITCHLOW. With 12 Figures	119
A. Introduction	119
B. Effects on Bacteria	124
C. Effects on DNA Gyrase	130
I. Reactions of Gyrase	130
II. Mechanistic Steps	131
1. DNA Binding	131
2. DNA Cleavage	133
3. ATPase	136
III. Illegitimate Recombination	137
IV. Summary	137
D. Mode of Binding	137
I. Binding of Quinolones to DNA	138
II. Effect of DNA Gyrase on Quinolone Binding	139
III. Cooperative Quinolone-DNA Binding Model	140
IV. DNA Cleavage is not an Absolute Requirement for Quinolone Binding to a Gyrase-DNA Complex	141
V. A Role for Magnesium Ions in the Binding of Quinolones to DNA	142
VI. Binding of Quinobenzoxazines to DNA	144

VII. Quinolone Binding to Quinolone-Resistant Mutants of DNA Gyrase	145
VIII. Mode of Binding of Topoisomerase II-Targeting Drugs ...	146
IX. Problems with Current Models	149
X. Conclusions	150
E. Mechanism of Cell Killing	150
I. Paradoxical Effects of Quinolones	150
II. Poison Hypothesis	153
III. Polymerase Blocking	153
F. Conclusions and Future Prospects	156
References	158

CHAPTER 5

The In Vitro Antibacterial Activity of Quinolones: A Review

C. THORNSBERRY	167
A. Introduction	167
B. In Vitro Activity	169
C. The Future	174
References	177

CHAPTER 6

Pharmacokinetics of Fluoroquinolones in Experimental Animals

A. DALHOFF and T. BERGAN. With 8 Figures	179
A. Introduction	179
B. Norfloxacin	180
C. Pefloxacin	181
D. Enoxacin	184
E. Ofloxacin	186
F. Ciprofloxacin	188
G. Temafloxacin	189
H. Tosufloxacin	191
I. Fleroxacin	191
J. Lomefloxacin	193
K. Sparfloxacin	195
L. Penetration of Quinolones at Sites of Infection	195
References	202

CHAPTER 7

Pharmacodynamics of Fluoroquinolones in Experimental Animals

W.A. CRAIG and A. DALHOFF. With 5 Figures	207
---	-----

A. Introduction	207
B. Bacterial Killing In Vivo	208
C. In Vivo Postantibiotic Effects	208
D. Pharmacodynamic Parameters Determining Efficacy	208
E. Emergence of Resistance to Fluoroquinolones	217
I. <i>P. aeruginosa</i> Experimental Infections	220
II. Staphylococcal Infections in Experimental Animals	222
III. Miscellaneous Infection Models	223
IV. Factors Contributing to the Emergence of Resistance	
In Vivo	223
References	226

CHAPTER 8

Interaction of Quinolones with Host-Parasite Relationship

A. DALHOFF. With 3 Figures	233
A. Introduction	233
B. Effect on Adherence	235
C. Effect Against Slowly Growing Bacteria	241
D. Effect on Exoenzyme Production	245
I. <i>E. coli</i>	245
II. <i>P. aeruginosa</i>	245
E. Quinolone-Induced Endotoxin Release	248
F. Summary	252
References	253

CHAPTER 9

Mechanisms of Resistance to Fluoroquinolones

M.J. EVERETT and L.J. V. PIDDOCK. With 5 Figures	259
A. Introduction	259
B. Target Site Modification	260
I. Mutations in <i>gyrA</i>	260
II. Mutations in <i>gyrB</i>	267
III. Mutations in Other Topoisomerase Genes	268
C. Reduced Intracellular Accumulation	270
I. Decreased Uptake	273
II. Increased Efflux	275
III. The <i>mar</i> Operon	277
D. Reduced Killing	278
E. Prevalence of Fluoroquinolone Resistance	281
I. Community Acquired Pathogens	281
II. Nosocomial Pathogens	282

III. Impact of Fluoroquinolone Use in Agriculture	284
F. Distribution of Resistance Mechanisms	285
G. Summary	286
References	286

CHAPTER 10

Toxicology and Safety Pharmacology of Quinolones

E. von KEUTZ and W. CHRIST. With 1 Figure	297
A. Introduction	297
B. Arthropathy	297
C. Achilles Tendinitis and Rupture	302
D. Nephropathy	304
E. Effects on Central Nervous System	306
F. Ocular Toxicity	313
G. Impairment of Spermatogenesis	315
H. Cardiovascular Effects	316
I. Possible Mutagenic and Carcinogenic Effects	317
J. Phototoxicity	322
K. Photocarcinogenicity and Photomutagenicity	327
L. Drug Interactions	329
M. Metabolic and Nutritional Effects	330
N. Conclusion	330
References	331

CHAPTER 11

Clinical Pharmacology

J. KUHLMANN, H.-G. SCHAEFER, and D. BEERMANN	339
A. Introduction	339
B. Pharmacokinetics of Fluoroquinolone Antibiotics	340
I. Healthy Subjects	341
1. Absorption	343
2. Intravenous Administration	346
3. Bioavailability	347
4. Distribution	347
5. Disposition	349
II. The Elderly	350
III. Patients with Various Degrees of Renal Failure	353
1. Ciprofloxacin	353
2. Norfloxacin	354
3. Ofloxacin	354
4. Enoxacin	354

5. Fleroxacin	354
6. Pefloxacin	354
7. Lomefloxacin	355
8. Summary	355
IV. Patients with Hepatic Failure	355
V. Fluoroquinolones in Pediatric Patients	356
C. Interactions of Fluoroquinolone Antibiotics with Other Drugs ...	357
I. Interactions During the Absorption Process	357
1. Food and Dairy Products	358
2. Al^{3+} -, Ca^{2+} - and Mg^{2+} -Containing Antacids	359
3. Sucralfate	361
4. Didanosine	362
5. Other Metal Cations	362
6. Chemotherapy Treatment	363
7. Activated Charcoal	364
II. Interactions of Fluoroquinolones Due to Alterations in Metabolism	365
1. Theophylline, Caffeine and Structurally Closely Related Substances	365
2. Antipyrine	370
3. Phenytoin	370
4. H_2 -Receptor Antagonists	371
5. K^+/Na^+ -ATPase Inhibitors	372
6. Warfarin	372
7. Cyclosporine	372
8. Rifampin	373
9. Oral Contraceptive Steroids	374
10. Benzodiazepines (Diazepam, Temazepam)	374
III. Alterations in Renal Excretion	375
1. Probenecid	375
2. β -Lactam Antibiotics	375
IV. Pharmacodynamic Interactions	376
1. Nonsteroidal Anti-inflammatory Drugs	376
2. Metronidazole	377
V. Conclusions	377
D. Adverse Reactions of Fluoroquinolones	378
I. Gastrointestinal Tract	379
II. Central Nervous System	379
III. Skin and Allergic Reactions	381
1. Photosensitivity	381
2. Photoallergy	384
IV. Nephropathy and Crystalluria	384
V. Arthropathy and Musculoskeletal Disorders	385
VI. Body Systems	385
VII. Others	386
References	386

CHAPTER 12

Concentration–Effect Relationship of the Fluoroquinolones

R. STAHLMANN and H. LODE. With 3 Figures	407
A. Introduction	407
B. Pharmacodynamic Data of Antimicrobials as a Basis for Clinical Use	408
I. β -Lactams: Concentration-Independent Killing Rate	408
II. Aminoglycosides: Concentration-Dependent Killing Rate	409
III. Fluoroquinolones	410
1. In Vitro Models	411
2. Animal Models	411
3. Clinical Data	414
4. Overall Evaluation of Pharmacodynamics	416
C. Pharmacokinetic Aspects	416
I. Protein Binding	417
II. Tissue Concentrations and Volume of Distribution	417
D. Summary and Conclusion	419
References	419

CHAPTER 13

Clinical Use of Quinolones

P. SCHACHT	421
A. Introduction	421
B. Urinary Tract Infections and Prostatitis	421
I. Acute Uncomplicated Urinary Tract Infection	422
II. Complicated Urinary Tract Infection	422
III. Prostatitis	422
C. Gastrointestinal Infections and Traveller's Diarrhea	425
I. <i>Salmonella typhi</i> – Enteric Fever	425
II. <i>Salmonella typhi</i> Carriers	426
III. <i>Salmonella</i> Gastroenteritis Outbreaks	427
IV. Shigellosis	427
V. Cholera	428
VI. Traveller's Diarrhea – Prevention	429
VII. Traveller's Diarrhea – Therapy	429
D. Respiratory Tract Infections	429
I. Acute Exacerbation of Chronic Bronchitis	430
II. Pneumonia	432
III. Recurrent Respiratory Tract Infections in Patients with Cystic Fibrosis	435
IV. Sinusitis	435
V. Bacterial Otitis (Chronic Suppurative Otitis Media)	436
VI. Malignant External Otitis	436

E. Osteomyelitis	437
F. Skin and Skin Structure Infection	438
G. Sexually Transmitted Diseases	439
I. Gonorrhea	439
II. Chancroid	440
III. Nongonococcal Urethritis	440
H. Intra-abdominal Infections	440
I. Anaerobic Intra-abdominal Infections	440
II. Cholangitis	441
III. Peritonitis in Chronic Ambulatory Dialysis Patients	441
IV. Gynecological Infections	441
I. Bacteremia and Sepsis	442
J. Surgical Prophylaxis	443
I. Transurethral Prostatic Surgery	443
II. Endoscopic Retrograde Cholangiopancreatography	443
III. Abdominal Surgery	443
K. Infections in Neutropenic Patients	444
I. Empirical Treatment of Febrile Neutropenic Patients	444
II. Prophylaxis in Neutropenic Cancer Patients	444
L. Use of Quinolones in Pediatrics	445
M. Remarks	445
References	445

CHAPTER 14

Future Aspects

S. SEGEV and E. RUBINSTEIN	455
A. Introduction	455
B. Molecular Structure and Mechanism of Action	455
C. Antimicrobial Activity	458
I. Gram-Positive Bacteria	459
1. Staphylococci	459
2. Streptococci	460
3. Enterococci	462
II. Anaerobic Bacteria	463
III. <i>Mycobacterium tuberculosis</i>	464
D. Bacterial Resistance	465
E. Future Use of Quinolones in Pediatrics	466
F. Antitumor Potential	467
G. New Attitudes	468
H. Directions of Future Research on the Quinolones	469
References	469

Subject Index	477
---------------------	-----